It may be that the negative images of banks and the federal government continue to persist in the minds of Americans because of the credit crisis. Or, perhaps people believe that the federal government has crippled the future of the economy because of an inability to set a budget and bring down deficits and control the national debt. Whatever the reasons might be, these two institutions are detested, when compared to others people encounter almost every day.
Results of a poll recently released by Gallup show that among the institutions with the worst perceptions by Americans are the federal government, banks and oil and gas companies. Probably oil spills and refinery fires undercut the public’s view of this sector. Problems with banks and the government are not so restricted. One way of viewing the perceptions of these two is that, because they are so broadly a part of American life, there is more to hate.
Banking activity covers as big a set of businesses as consumer loans, mortgages, credit cards and savings. What could have gone wrong with most of these did go wrong in the past few years. Millions of mortgages went sour as housing prices crashed. Banks did nothing to help homeowners adjust their mortgage obligations to save their homes. Overcharging for credit card debt has become so broad a topic that it is often on the front pages. The yield on most savings rarely rises above 1%.
10 Best Clean Energy Stocks To Watch For 2015: Post Properties Inc. (PPS)
Post Properties, Inc., a real estate investments trust (REIT), together with its subsidiaries, engages in the development, ownership, and management of multifamily apartment communities in the United States. As of December 31, 2007, the company owned 22,578 apartment units in 63 apartment communities, including 1,747 apartment units in 2 communities held in unconsolidated entities and 2,266 apartment units in 7 communities. It is also developing and selling 535 for-sale condominium homes in 4 communities and converting 349 apartment homes into for-sale condominium homes in 2 communities. The company primarily operates in Atlanta, Georgia; Dallas, Texas; Washington, D.C.; and Tampa, Florida metropolitan areas. Post Properties has elected to be taxed as REIT under the Internal Revenue Code and would not be subject to federal income taxes, if it distributes approximately 90% of its taxable income to its shareholders. The company was founded in 1971 and is based in Atlanta, Ge orgia.
Advisors' Opinion:- [By Philip Springer]
Post Properties Inc. (NYSE: PPS): 14.7%
Here are the largest homebuilders and their shares’ performance so far this year:
Lennar Corp. (NYSE: LEN): -2.3%
Top 5 Integrated Utility Companies To Invest In Right Now: PetMed Express Inc.(PETS)
PetMed Express, Inc., doing business as 1-800-PetMeds, operates a pet pharmacy in the United States. It markets non-prescription and prescription pet medications; and other health products for dogs and cats, as well as direct to consumers. The company?s non-prescription medications include flea and tick control products, bone and joint care products, vitamins and nutritional supplements, and hygiene products. Its prescription medications comprise heartworm preventatives; arthritis, thyroid, diabetes, and pain medications; antibiotics and other specialty medications; and generic substitutes. In addition, the company, through its Web site, 1800petmeds.com, sells beds, crates, stairs, strollers, and other pet supplies. PetMed Express offers its products under the Frontline Plus, K9 Advantix, Advantage, Heartgard Plus, Sentinel, Interceptor, Program, Revolution, Deramaxx, and Rimadyl brands. The company markets its products through national television, online, and direct mail /print advertising campaigns, as well as through telephone, catalogs, brochures, and postcards. It primarily serves retail customers. PetMed Express was founded in 1996 and is headquartered in Pompano Beach, Florida.
Advisors' Opinion:- [By Bryan Murphy]
The two-year soft patch for Petmed Express Inc. (NASDAQ:PETS) may well be over; we'll know for sure on Monday. The two-year dry spell for faithful PETS shareholders may also be over. In fact, the chart says the stock's already in a new uptrend, and the company has a chance to cement that budding move into place when earnings are unveiled early next week.
- [By Monica Gerson]
PetMed Express (NASDAQ: PETS) is projected to report its Q3 earnings at $0.23 per share on revenue of $52.06 million.
Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets
Top 5 Integrated Utility Companies To Invest In Right Now: Golar LNG Partners LP (GMLP)
Golar LNG Partners LP (the Partnership), incorporated on September 24, 2007, is a limited partnership formed as a wholly owned subsidiary of Golar LNG Limited (Golar), an independent owner and operator of floating storage re-gasification units (FSRUs) and liquefied natural gas (LNG) carriers, to own and operate FSRUs and LNG carriers under long-term charters. The vessels in its fleet are chartered to BG Group, Pertamina, Petrobras and Dubai Supply Authority. As of December 31, 2012, Golar owned its 2.0% general partner interest, all of its IDRs and a 49.9% limited partner interest in it. As of December 31, 2012, its fleet consisted of a 100% interest in the Golar Spirit, which is operating under a time charter with Petrobras; a 100% interest in the Golar Winter, which is operating under a time charter with Petrobras; a 100% interest in the Golar Freeze, which is operating under a time charter with Dubai Supply Authority (DUSUP), the purchaser of natural gas in Dubai; a 100% interest in the Methane Princess, which is operating under a time charter with BG Group PLC (BG Group), and a 60% interest in the Golar Mazo, an LNG carrier, which is operating under a time charter with PT Pertamina (Pertamina). In July 2012, Golar sold its interests in the companies that own and operate the floating storage and regasification unit (FSRU) Nusantara Regas Satu to the Company. As of April 30, 2013, the Company has a fleet of four FSRUs and four LNG carriers. In November 2012, the Company acquired from Golar interests in subsidiaries that lease and operate the LNG carrier, the Golar Grand.
FSRU Charters
The Company provides the services of each of the Golar Spirit and the Golar Winter to Petrobras under separate time charter parties (or TCP) and operation and services agreements (OSAs). The TCPs and OSAs are interdependent and when combined have the same effect as the time charters for its LNG carriers. The services of the Golar Freeze are provided to DUSUP under a TCP. The Golar Spirit and ! Golar Winter charters also contained provisions giving Petrobras the option to purchase the vessels from it under certain circumstances.
LNG Carrier Charters
The Company provides the LNG marine transportation services of the Golar Mazo, Methane Princess and the Golar Maria under a time charters with LNG Shipping SpA. A time charter is a contract for the use of the vessel for a fixed period of time at a specified daily rate. Under a time charter, the vessel owner provides crewing and other services related to the vessel�� operation.
The Company competes with Royal Dutch Shell, BP, BG, Malaysian International Shipping Company, National Gas Shipping Company, Qatar Gas Transport Company, Excelerate Energy, Hoegh LNG, Exmar, Teekay LNG and MISC Berhad.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Golar LNG Partners Limited Partnership (Nasdaq: GMLP ) , whose recent revenue and earnings are plotted below. - [By James E. Brumley]
I'll warn you now at least some of you aren't going to like what you're about to hear. But, I wouldn't be doing any one a service by ignoring an important reality. So, here goes - shares of Golar LNG Limited (NASDAQ:GLNG) and its mater/parent Golar LNG Partners LP (NASDAQ:GMLP) are ripe for a sizeable pullback. Anybody who was mulling a new position in GMLP or GLNG here may want to hold off just a bit, and anybody who stepped into either or both within the past month or so may want to go ahead and lock in their nice gain while they can.
- [By Roberto Pedone]
Golar LNG Partners LP (GMLP), a limited partnership, owns and operates floating storage and regasification units and LNG carriers under long-term charters. This stock closed up 3.5% at $32.74 in Monday's trading session.
Monday's Volume: 432,000
Three-Month Average Volume: 81,559
Volume % Change: 283%From a technical perspective, GMLP bounced notably higher here right off its 200-day moving average of $31.79 and back above its 50-day moving average of $32.56 with strong upside volume. This move is quickly pushing shares of GMLP within range of triggering a near-term breakout trade. That trade will hit if GMLP manages to take out Monday's intraday high at $32.96 to some more near-term overhead resistance at $33.15 with high volume.
Traders should now look for long-biased trades in GMLP as long as it's trending above its 200-day at $31.79 and then once it sustains a move or close above those breakout levels with volume that's near or above 81,559 shares. If that breakout hits soon, then GMLP will set up to re-test or possibly take out its next major overhead resistance levels at $34.78 to its 52-week high at $36.
Top 5 Integrated Utility Companies To Invest In Right Now: Tetraphase Pharmaceuticals Inc (TTPH)
Tetraphase Pharmaceuticals, Inc., incorporated on July 7, 2006, is a clinical stage biopharmaceutical company. The Company�� product candidate, eravacycline, is a fully synthetic tetracycline derivative that the Company are developing as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections. The Company�� frequently used products, such as Zyvox and Cubicin, are limited to Gram-positive bacteria and thus are rarely used as a first-line empiric monotherapy if broad bacterial coverage is required. During the year ended December 31, 2012, completed a Phase 2 clinical trial of eravacycline with intravenous administration for the treatment of patients with complicated intra-abdominal infections, or cIAI, and are finalizing its pivotal Phase 3 program for eravacycline. In 2012, in vitro experiments, eravacycline has demonstrated the ability to cover a variety of multi-drug resistant Gram-negative, Gram-positive, anaerobic and atypical bacteria, including multi-drug resistant Klebsiella pneumoniae, the species of Gram-negative bacteria that killed seven patients at the Clinical Center of the National Institutes of Health.
Gram-positive bacteria that have developed resistance to existing drugs include: Streptococcus pneumoniae that cause pneumonia, ear infections, bloodstream infections and meningitis; Staphylococcus aureus that cause skin, bone, lung and bloodstream infections, and Enterococci that are responsible for infections transmitted in healthcare settings. Gram-negative bacteria that have developed resistance to existing drugs include: Escherichia coli that cause urinary tract, skin and bloodstream infections; Salmonella and Escherichia coli that cause foodborne infections, and Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella spp.
In addition, other antibiotics that have been used as first-line empiric monothe! rapies, such as Levaquin, piperacillin/tazobactam, which is marketed by Pfizer as Zosyn, carbapenems, such as Merrem, and imipenem/cilastatin, which is marketed by Merck as Primaxin, have seen their utility as first-line empiric monotherapies diminished as the number of bacterial strains resistant to these therapies has increased. In addition to developing an intravenous formulation of eravacycline, the Company is also developing an oral formulation. A number of previous tetracyclines have been available in both intravenous and oral dosage forms. Infections that are resistant to existing oral drugs are increasingly common, and the Company believe that an intravenous-to-oral step-down therapy in which patients are started on the intravenous formulation of eravacycline and then stepped down to an oral formulation of eravacycline could reduce the length of a patient�� hospital stay or help avoid hospital admission altogether, lowering the overall cost of care for these patients.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 biopharmaceutical player that's starting to trend within range of triggering a near-term breakout trade is Tetraphase Pharmaceuticals (TTPH), which using its proprietary chemistry technology creates novel antibiotics for serious and life-threatening multi-drug resistant infections. This stock is off to a strong start in 2013, with shares up 19.4%.
If you take a look at the chart for Tetraphase Pharmaceuticals, you'll notice that this stock has just started to trend back above its 50-day moving average of $7.76 a share with decent upside volume flows. That move is quickly pushing shares of TTPH within range of breaking out above some key near-term overhead resistance levels that have acted as a ceiling for the stock for the last three months.
Market players should now look for long-biased trades in TTPH if it manages to break out above some near-term overhead resistance levels at $8.30 to $8.40 a share and then once it takes out more resistance at $8.50 to $9 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average volume of 62,234 shares. If that breakout triggers soon, then TTPH will set up to re-test or possibly take out its all-time high at $9.66 a share. Any high-volume move above that level will then push TTPH into new all-time high territory, which is bullish technical price action. Some possible upside targets off that move are $12 to $13 a share.
Traders can look to buy TTPH off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $7.76 a share, or below more key near-term support levels at $7.37 to $7.02 a share. One can also buy TTPH off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
No comments:
Post a Comment